Ovarian Cancer Market Report

China Ovarian Cancer Industry Market Research Report 2023-2029

  • POSTDATE：Sep 07, 2023
  • PAGES：170
  • REPORT CODE：GMM1781704
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Ovarian Cancer industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • PharmaMar SA

    • Oasmia Pharmaceuticals, Inc

    • Merck & Co, Inc

    • Incyte Corporation

    • GlaxoSmithKline plc (Tesaro)

    • AstraZeneca plc (Acerta Pharma)

    • Clovis Oncology

    • MacroGenics, Inc

    • Pfizer, Inc

    • Five Prime Therapeutics, Inc

    • Roche Holding AG

    • Boehringer Ingelheim GmbH

    • Novartis AG

    • Gradalis, Inc

    • Mateon Therapeutics, Inc

    By Type:

    • PARP Inhibitors

    • Angiogenesis Inhibitors

    • PD-L1 Inhibitors

    By Application:

    • Immunotherapy

    • Targeted Therapy

    • Chemotherapy

    • Others

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Ovarian Cancer Market Overview 2018-2029

    • 1.1 China Ovarian Cancer Industry Development Overview

    • 1.2 China Ovarian Cancer Industry Development History

    • 1.3 China Ovarian Cancer Industry Market Size (2018-2029)

    • 1.4 China Ovarian Cancer Market Analysis by Type from Production Side

      • 1.4.1 China Ovarian Cancer Production Volume, Production Value and Growth Rate of PARP Inhibitors (2018-2029)

      • 1.4.2 China Ovarian Cancer Production Volume, Production Value and Growth Rate of Angiogenesis Inhibitors (2018-2029)

      • 1.4.3 China Ovarian Cancer Production Volume, Production Value and Growth Rate of PD-L1 Inhibitors (2018-2029)

    • 1.5 China Ovarian Cancer Market Analysis by Application from Consumption End

      • 1.5.1 China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Immunotherapy (2018-2029)

      • 1.5.2 China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Targeted Therapy (2018-2029)

      • 1.5.3 China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Chemotherapy (2018-2029)

      • 1.5.4 China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

    • 1.6 China Ovarian Cancer Market Analysis by Region

      • 1.6.1 North China Ovarian Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Ovarian Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Ovarian Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Ovarian Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Ovarian Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Ovarian Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    Chapter 2 China Ovarian Cancer Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Ovarian Cancer Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Ovarian Cancer Market Status and Competition Analysis in 2023

      • 2.2.3 China Ovarian Cancer Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Ovarian Cancer Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Ovarian Cancer Industry Development

    Chapter 3 Ovarian CancerIndustry Chain Analysis

    • 3.1 Ovarian Cancer Industry Chain

    • 3.2 Ovarian Cancer Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Ovarian Cancer Market

    • 3.3 Ovarian Cancer Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Ovarian Cancer Market

    Chapter 4 China Ovarian Cancer Market, by Type

    • 4.1 China Ovarian Cancer Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Ovarian Cancer Total Production Volume and Growth Rate from Production Side

    • 4.5 China Ovarian Cancer Production Volume and Growth Rate, by Type

      • 4.5.1 China Ovarian Cancer Production Volume and Growth Rate of PARP Inhibitors

      • 4.5.2 China Ovarian Cancer Production Volume and Growth Rate of Angiogenesis Inhibitors

      • 4.5.3 China Ovarian Cancer Production Volume and Growth Rate of PD-L1 Inhibitors

    Chapter 5 China Ovarian Cancer Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Ovarian Cancer Total Market Size and Growth Rate from Consumption End

    • 5.5 China Ovarian Cancer Market Size and Growth Rate, by Application

      • 5.5.1 China Ovarian Cancer Market Size and Growth Rate of Immunotherapy

      • 5.5.2 China Ovarian Cancer Market Size and Growth Rate of Targeted Therapy

      • 5.5.3 China Ovarian Cancer Market Size and Growth Rate of Chemotherapy

      • 5.5.4 China Ovarian Cancer Market Size and Growth Rate of Others

    Chapter 6 China Ovarian Cancer Market, by Region

    • 6.1 China Ovarian Cancer Production Volume and Production Value, by Region

    • 6.2 China Ovarian Cancer Sales Volume and Sales Value, by Region

    Chapter 7 North China Ovarian Cancer Market Analysis

    • 7.1 North China Ovarian Cancer Market, by Type

    • 7.2 North China Ovarian Cancer Market, by Application

    Chapter 8 Central China Ovarian Cancer Market Analysis

    • 8.1 Central China Ovarian Cancer Market, by Type

    • 8.2 Central China Ovarian Cancer Market, by Application

    Chapter 9 South China Ovarian Cancer Market Analysis

    • 9.1 South China Ovarian Cancer Market, by Type

    • 9.2 South China Ovarian Cancer Market, by Application

    Chapter 10 East China Ovarian Cancer Market Analysis

    • 10.1 East China Ovarian Cancer Market, by Type

    • 10.2 East China Ovarian Cancer Market, by Application

    Chapter 11 Northeast China Ovarian Cancer Market Analysis

    • 11.1 Northeast China Ovarian Cancer Market, by Type

    • 11.2 Northeast China Ovarian Cancer Market, by Application

    Chapter 12 Southwest China Ovarian Cancer Market Analysis

    • 12.1 Southwest China Ovarian Cancer Market, by Type

    • 12.2 Southwest China Ovarian Cancer Market, by Application

    Chapter 13 Northwest China Ovarian Cancer Market Analysis

    • 13.1 Northwest China Ovarian Cancer Market, by Type

    • 13.2 Northwest China Ovarian Cancer Market, by Application

    Chapter 14 Company Profiles

      • 14.1 PharmaMar SA

        • 14.1.1 PharmaMar SA Company Profile

        • 14.1.2 PharmaMar SA Ovarian Cancer Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Oasmia Pharmaceuticals, Inc

        • 14.2.1 Oasmia Pharmaceuticals, Inc Company Profile

        • 14.2.2 Oasmia Pharmaceuticals, Inc Ovarian Cancer Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Merck & Co, Inc

        • 14.3.1 Merck & Co, Inc Company Profile

        • 14.3.2 Merck & Co, Inc Ovarian Cancer Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Incyte Corporation

        • 14.4.1 Incyte Corporation Company Profile

        • 14.4.2 Incyte Corporation Ovarian Cancer Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 GlaxoSmithKline plc (Tesaro)

        • 14.5.1 GlaxoSmithKline plc (Tesaro) Company Profile

        • 14.5.2 GlaxoSmithKline plc (Tesaro) Ovarian Cancer Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 AstraZeneca plc (Acerta Pharma)

        • 14.6.1 AstraZeneca plc (Acerta Pharma) Company Profile

        • 14.6.2 AstraZeneca plc (Acerta Pharma) Ovarian Cancer Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Clovis Oncology

        • 14.7.1 Clovis Oncology Company Profile

        • 14.7.2 Clovis Oncology Ovarian Cancer Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 MacroGenics, Inc

        • 14.8.1 MacroGenics, Inc Company Profile

        • 14.8.2 MacroGenics, Inc Ovarian Cancer Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Pfizer, Inc

        • 14.9.1 Pfizer, Inc Company Profile

        • 14.9.2 Pfizer, Inc Ovarian Cancer Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 Five Prime Therapeutics, Inc

        • 14.10.1 Five Prime Therapeutics, Inc Company Profile

        • 14.10.2 Five Prime Therapeutics, Inc Ovarian Cancer Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Roche Holding AG

        • 14.11.1 Roche Holding AG Company Profile

        • 14.11.2 Roche Holding AG Ovarian Cancer Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Boehringer Ingelheim GmbH

        • 14.12.1 Boehringer Ingelheim GmbH Company Profile

        • 14.12.2 Boehringer Ingelheim GmbH Ovarian Cancer Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Novartis AG

        • 14.13.1 Novartis AG Company Profile

        • 14.13.2 Novartis AG Ovarian Cancer Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Gradalis, Inc

        • 14.14.1 Gradalis, Inc Company Profile

        • 14.14.2 Gradalis, Inc Ovarian Cancer Market Performance

        • 14.14.3 Product&Service Introduction

      • 14.15 Mateon Therapeutics, Inc

        • 14.15.1 Mateon Therapeutics, Inc Company Profile

        • 14.15.2 Mateon Therapeutics, Inc Ovarian Cancer Market Performance

        • 14.15.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Ovarian Cancer Industry Research Conclusions

    • 15.2 Ovarian Cancer Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Ovarian Cancer Industry Market Size (2018-2029)

    • Figure China Ovarian Cancer Production Volume, Production Value and Growth Rate of PARP Inhibitors (2018-2029)

    • Figure China Ovarian Cancer Production Volume, Production Value and Growth Rate of Angiogenesis Inhibitors (2018-2029)

    • Figure China Ovarian Cancer Production Volume, Production Value and Growth Rate of PD-L1 Inhibitors (2018-2029)

    • Figure China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Immunotherapy (2018-2029)

    • Figure China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Targeted Therapy (2018-2029)

    • Figure China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Chemotherapy (2018-2029)

    • Figure China Ovarian Cancer Sales Volume, Sales Value and Growth Rate of Others (2018-2029)

    • Figure North China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure Central China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure South China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure East China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Ovarian Cancer Market Size and Growth Rate from 2018-2029

    • Figure Ovarian Cancer Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Ovarian Cancer Market Share by Type in 2018

    • Figure China Ovarian Cancer Market Share by Type in 2023

    • Figure China Ovarian Cancer Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Ovarian Cancer Production Volume and Growth Rate of PARP Inhibitors (2018-2023)

    • Figure China Ovarian Cancer Production Volume and Growth Rate of Angiogenesis Inhibitors (2018-2023)

    • Figure China Ovarian Cancer Production Volume and Growth Rate of PD-L1 Inhibitors (2018-2023)

    • Figure China Ovarian Cancer Market Share by Application in 2018

    • Figure China Ovarian Cancer Market Share by Application in 2023

    • Figure China Ovarian Cancer Total Market Size and Growth Rate from Consumption End

    • Figure China Ovarian Cancer Market Size and Growth Rate of Immunotherapy (2018-2023)

    • Figure China Ovarian Cancer Market Size and Growth Rate of Targeted Therapy (2018-2023)

    • Figure China Ovarian Cancer Market Size and Growth Rate of Chemotherapy (2018-2023)

    • Figure China Ovarian Cancer Market Size and Growth Rate of Others (2018-2023)

    • Table China Ovarian Cancer Production Volume by Region (2018-2023)

    • Table China Ovarian Cancer Production Volume Share by Region (2018-2023)

    • Figure China Ovarian Cancer Production Volume Share by Region (2018-2023)

    • Table China Ovarian Cancer Production Value by Region (2018-2023)

    • Table China Ovarian Cancer Production Value Share by Region (2018-2023)

    • Figure China Ovarian Cancer Production Value Share by Region (2018-2023)

    • Table China Ovarian Cancer Sales Volume by Region (2018-2023)

    • Table China Ovarian Cancer Sales Volume Share by Region (2018-2023)

    • Figure China Ovarian Cancer Sales Volume Share by Region (2018-2023)

    • Table China Ovarian Cancer Sales Value by Region (2018-2023)

    • Table China Ovarian Cancer Sales Value Share by Region (2018-2023)

    • Figure China Ovarian Cancer Sales Value Share by Region (2018-2023)

    • Table North China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table North China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure North China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table North China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table North China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure North China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table Central China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table Central China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure Central China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table Central China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table Central China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure Central China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table South China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table South China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure South China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table South China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table South China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure South China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table East China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table East China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure East China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table East China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table East China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure East China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table Northeast China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table Northeast China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure Northeast China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table Northeast China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table Northeast China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table Southwest China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table Southwest China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure Southwest China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table Southwest China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table Southwest China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table Northwest China Ovarian Cancer Production Volume by Type (2018-2023)

    • Table Northwest China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Figure Northwest China Ovarian Cancer Production Volume Share by Type (2018-2023)

    • Table Northwest China Ovarian Cancer Sales Volume by Application (2018-2023)

    • Table Northwest China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Ovarian Cancer Sales Volume Share by Application (2018-2023)

    • Table PharmaMar SA Company Profile

    • Table PharmaMar SA Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Oasmia Pharmaceuticals, Inc Company Profile

    • Table Oasmia Pharmaceuticals, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Merck & Co, Inc Company Profile

    • Table Merck & Co, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Incyte Corporation Company Profile

    • Table Incyte Corporation Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline plc (Tesaro) Company Profile

    • Table GlaxoSmithKline plc (Tesaro) Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table AstraZeneca plc (Acerta Pharma) Company Profile

    • Table AstraZeneca plc (Acerta Pharma) Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Clovis Oncology Company Profile

    • Table Clovis Oncology Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table MacroGenics, Inc Company Profile

    • Table MacroGenics, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Pfizer, Inc Company Profile

    • Table Pfizer, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Five Prime Therapeutics, Inc Company Profile

    • Table Five Prime Therapeutics, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Roche Holding AG Company Profile

    • Table Roche Holding AG Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Boehringer Ingelheim GmbH Company Profile

    • Table Boehringer Ingelheim GmbH Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Novartis AG Company Profile

    • Table Novartis AG Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Gradalis, Inc Company Profile

    • Table Gradalis, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)

    • Table Mateon Therapeutics, Inc Company Profile

    • Table Mateon Therapeutics, Inc Ovarian Cancer Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US